2023 Annual Symposium For Evolving Therapies and Drug Development in Oncology: Targeted therapy, immunotherapy and beyond

Herndon, VA US
September 29, 2023 to September 30, 2023

This CME-accredited activity, “2023 Annual Symposium for Evolving Therapies and Drug Development in Oncology: Targeted therapy, immunotherapy and beyond”, is a two-day conference aimed at improving the knowledge and competence of academic and community oncology providers on the biomarker-guided treatment of cancer, and design and conduct of clinical trials in the era of novel therapies. The activity will use a mix of didactic lectures and panel discussions to highlight various aspects of precision oncology, including current challenges and opportunities in designing clinical trials in the era of novel therapies.

Target Audience

  • Hematology/Oncology physicians
  • NPs/PAs
  • Residents/fellows
  • Pharmacists
  • Nurses

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  • Review recent updates in biomarker-guided treatment options for cancer patients.
  • Review challenges and trends in drug development in the era of novel therapies.
  • Outline the best practices for the conduct of Phase I clinical trials in the era of novel therapies.
  • Identify the phase I clinical trials to match patients’ needs.
  • Review the challenges and potential solutions for the diverse representation during drug development.
Course summary
Course opens: 
05/01/2023
Course expires: 
09/29/2024
Event starts: 
09/29/2023 - 3:00pm PDT
Event ends: 
09/30/2023 - 5:00pm PDT
Cost:
$100.00
Add to calendar: 

Conference Chairs: Nagla Abdel Karim, MD and Vivek Subbiah, MD

Day 1 - September 29, 2023

All times below are listed in Eastern Standard Time (EST).

3:00 PM - 4:00 PM Registration/Networking 

4:00 PM - 4:15 PM Welcome note 

4:15 PM - 5:15 PM SESSION I. EVOLVING TARGETED THERAPIES

Chair: Raymond Wadlow, MD

4:15 PM - 4:30 PM Tumor Agnostic Drug Development - Vivek Subbiah, MD

4:30 PM - 4:45 PM Cracking the KRAS Code: Novel Approaches to Targeting KRAS - Nagla Abdel Karim, MD

4:45 PM - 5.15 PM Panel Discussion 

Panelists: Safae Chouraichi, PharmD, BCOP, Simona Armanca, PharmD


Day 2 - September 30, 2023

7:00 AM - 8:00 AM Registration, Breakfast and Networking

8:00 AM - 8:30 AM Special Session I. Update on NCI-Sponsored Early Trial Program

Chair: Matthew Reilly, MD

Speaker: Elad Sharon, MD

8:30 AM - 9:30 AM SESSION II. EVOLVING IMMUNOTHERAPY LANDSCAPE 

Chair: Matthew Reilly, MD 

8:30 AM - 8:45 AM Novel Immunotherapies: Beyond PD1/CTLA4 and LAG3 -  Ludimila Cavalcante, MD

8:45 AM - 9:00 AM Cellular Therapies in Phase I Programs -  John Powderly, MD

9:00 AM - 9:30 AM Panel Discussion

Panelists:  Hatim Husain, MD

9:30 AM - 9:45 AM Coffee Break and Exhibits

9:45 AM - 10:15 AM Keynote Lecture: The FDA Perspective on Early Phase Pre-Market Dose Optimization

Chair: John Deeken, MD

Speaker: Paul Kluetz, MD

10:15 AM -10:45 AM Special Session II. Mastering the First Step: Essential Tools for Aspiring Clinical Investigators in Phase I Trials” Aspiring Clinical Investigators

Moderators: Ludimila Cavalcante, MD

Panelists: Raymond Wadlow, MD 

10:45 AM - 11:45 AM SESSION III. REVOLUTIONIZING CLINICAL TRIALS WITH PRECISION ONCOLOGY: A GAME CHANGER IN CANCER TREATMENT

Chair:  

10:45 AM - 11:00 AM The Perfect Match: Tailoring Personalized Therapies and Clinical Trials for Optimal Patient Outcomes - Michael Pishvaian, MD

11:00 AM - 11:15 AM “LUNGMAP study; Connecting Patients with Cutting-Edge Therapies” - Jonathan Riess, MD

11:15 AM - 11:30 AM The Role of Liquid Biopsy in Phase I Clinical Trials - Christian Rolfo, MD

11:30 AM - 11:45 PM Molecular Tumor Board Cases & Panel Discussion 

Panelists: Timothy Cannon, MD

11:45 AM - 12:45 PM: Lunch and Exhibits

12:45 PM - 1:45 PM SESSION IV. BREAKING BARRIERS: IMPACT OF DIVERSITY AND SPECIALIZED CARE OF RARE TUMORS

Chair:  Stephen Liu, MD

12:45 PM - 1:00 PM Increasing Diversity in Clinical Trials To Reduce Health Disparities: The Time is Now -  Estella Rodriguez, MD

1:00 PM - 1:15 PM Updates from DART Study 

1:15 PM - 1:30 PM Novel Therapies for Brain Metastases -  Manmeet Ahluwalia, MD, MBA, FASCO

1:30 PM - 1:45 PM Panel Discussion

Panelists:  Enum (Angel) Yu, MD

1:45 PM - 2:00 PM Coffee Break and Exhibits

2:00 PM - 3:00 PM SESSION V. FUTURE THERAPIES

Chair: 

2:00 PM - 2:30 PM Future of Drug Development in Oncology - 3 Pillars (10 min talks)

2:00 PM - 2:10 PM Precision medicine and beyond CRSPR/ Microbiome 

2:10 PM - 2:20 PM ADC 

2:20 PM - 2:30 PM How Innovative Therapies are Breaking Barriers for Small Cell Lung Cancer - Asrar AlAhmadi, MD

2:30 PM - 3:00 PM Panel Discussion and Q&As 

Panelists:  Triparna Sen, MD

3:00 PM - 3:30 PM Special Session III. Laying the Foundation: “Steps to Build a Successful Phase I Program”

Moderator: TBD

Panelists: Elad Sharon, MD, John Powderly, MD, Stéphanie Gaillard, MD PhD

3:30 PM - 3:45 PM Coffee Break

3:45 PM - 4:45 PM SESSION VI. BEYOND THE NUMBERS: NEW PERSPECTIVES ON MEASUREMENTS OF SUCCESS 

Chair: Michael Winkler, MD

3:45 PM - 4:00 PM Taking RECIST Measurements into Consideration - Daniel Margolis, MD

4:00 PM - 4:15 PM Artificial Intelligence in Medicine - Heejong Kim, PhD

4:15 PM - 4:45 PM Panel Discussion

Panelists: Tara Berman, MD

4:45PM - 5:00 PM Closing Remarks   

Hyatt Regency Dulles
2300 Dulles Corner Blvd
Herndon, VA 20171
United States
Course Director(s)

Nagla Abdel Karim, MD, PhD

has a financial relationship (Professional Services) with Jazz, Regeneron, Amgen;.
has a financial relationship (Other) with BMS, Exelixis, Pfizer, Astra Zeneca;.

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.
Moderator(s)

Raymond Wadlow

has a financial relationship (Independent contractor) with Taiho;.
has a financial relationship (Independent contractor) with Exact Sciences;.
has a financial relationship (Independent contractor) with Seagen;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Independent contractor) with Johnson & Johnson;.
Planner(s)

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.
Speaker(s)

Nagla Abdel Karim, MD, PhD

has a financial relationship (Professional Services) with Jazz, Regeneron, Amgen;.
has a financial relationship (Other) with BMS, Exelixis, Pfizer, Astra Zeneca;.

Safae Chouraichi, PharmD, BCOP

has no relevant financial relationships to disclose at this time.

Heejong Kim

has no relevant financial relationships to disclose at this time.

Daniel Margolis, MD

has a financial relationship (Other) with Promaxo;.

Jonathan Riess, MD, MS

has a financial relationship (Professional Services) with Bayer;.
has a financial relationship (Professional Services) with Regeneron;.
has a financial relationship (Professional Services) with Biodesix;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Beigene;.
has a financial relationship (Professional Services) with Boehringer Ingelheim;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Independent contractor) with Genentech;.
has a financial relationship (Professional Services) with Jazz Pharmaceuticals;.
has a financial relationship (Professional Services) with Boehringer Ingelheim;.
has a financial relationship (Professional Services) with Turning Point;.
has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Professional Services) with EMD Serano;.

Eun-mi Yu, Eun-mi Yu, MD

has no relevant financial relationships to disclose at this time.

Accreditation information coming soon

Price

Cost:
$100.00
Please login or register to take this course.

REGISTRATION FEES 

Physicians (non-industry) - $100

Non-physician HCP (non-industry) - $75

Industry representatives - $1250

Fellows/Residents - $0

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.